United Laboratories International Holdings Past Earnings Performance
Past criteria checks 5/6
United Laboratories International Holdings has been growing earnings at an average annual rate of 33.8%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 12.6% per year. United Laboratories International Holdings's return on equity is 21.4%, and it has net margins of 20.8%.
Key information
33.8%
Earnings growth rate
32.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.6% |
| Revenue growth rate | 12.6% |
| Return on equity | 21.4% |
| Net Margin | 20.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
These 4 Measures Indicate That United Laboratories International Holdings (HKG:3933) Is Using Debt Safely
Nov 11
The United Laboratories International Holdings Limited (HKG:3933) Stock Catapults 29% Though Its Price And Business Still Lag The Market
Oct 23Here's Why We Think United Laboratories International Holdings (HKG:3933) Is Well Worth Watching
Aug 30Improved Earnings Required Before The United Laboratories International Holdings Limited (HKG:3933) Stock's 26% Jump Looks Justified
Feb 29The United Laboratories International Holdings Limited's (HKG:3933) Low P/E No Reason For Excitement
Jan 04United Laboratories International Holdings (HKG:3933) Could Easily Take On More Debt
Dec 14With EPS Growth And More, United Laboratories International Holdings (HKG:3933) Makes An Interesting Case
Nov 26Is United Laboratories International Holdings (HKG:3933) A Risky Investment?
Aug 31Does United Laboratories International Holdings (HKG:3933) Deserve A Spot On Your Watchlist?
Aug 10United Laboratories International Holdings (HKG:3933) Has A Rock Solid Balance Sheet
Dec 23Are Investors Undervaluing The United Laboratories International Holdings Limited (HKG:3933) By 47%?
Oct 19Is United Laboratories International Holdings (HKG:3933) Using Too Much Debt?
Aug 30Is The United Laboratories International Holdings Limited (HKG:3933) A Smart Pick For Income Investors?
Mar 08The United Laboratories International Holdings (HKG:3933) Share Price Is Up 108% And Shareholders Are Boasting About It
Feb 18
The United Laboratories International Holdings Limited's (HKG:3933) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Feb 03Did The United Laboratories International Holdings Limited (HKG:3933) Insiders Sell Shares?
Jan 19We Wouldn't Rely On United Laboratories International Holdings's (HKG:3933) Statutory Earnings As A Guide
Jan 04These 4 Measures Indicate That United Laboratories International Holdings (HKG:3933) Is Using Debt Safely
Dec 20What Type Of Shareholders Own The Most Number of The United Laboratories International Holdings Limited (HKG:3933) Shares?
Dec 07The United Laboratories International Holdings Limited (HKG:3933) Is Yielding 1.3% - But Is It A Buy?
Nov 23Revenue & Expenses Breakdown
How United Laboratories International Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 14,009 | 2,908 | 2,120 | 108 |
| 31 Mar 24 | 13,875 | 2,805 | 2,255 | 54 |
| 31 Dec 23 | 13,740 | 2,701 | 2,389 | 0 |
| 30 Sep 23 | 13,399 | 2,469 | 2,475 | 48 |
| 30 Jun 23 | 13,059 | 2,236 | 2,561 | 96 |
| 31 Mar 23 | 12,197 | 1,909 | 2,456 | 48 |
| 31 Dec 22 | 11,334 | 1,581 | 2,350 | 0 |
| 30 Sep 22 | 10,750 | 1,288 | 2,376 | 20 |
| 30 Jun 22 | 10,166 | 995 | 2,402 | 39 |
| 31 Mar 22 | 9,935 | 991 | 2,368 | 20 |
| 31 Dec 21 | 9,703 | 988 | 2,334 | 0 |
| 30 Sep 21 | 9,445 | 1,056 | 2,304 | 20 |
| 30 Jun 21 | 9,187 | 1,123 | 2,273 | 40 |
| 31 Mar 21 | 8,980 | 913 | 2,248 | 20 |
| 31 Dec 20 | 8,772 | 703 | 2,222 | 0 |
| 30 Sep 20 | 8,690 | 626 | 2,175 | 22 |
| 30 Jun 20 | 8,607 | 549 | 2,128 | 44 |
| 31 Mar 20 | 8,500 | 595 | 2,172 | 22 |
| 31 Dec 19 | 8,393 | 642 | 2,216 | 0 |
| 30 Sep 19 | 8,100 | 765 | 2,147 | 9 |
| 30 Jun 19 | 7,808 | 888 | 2,077 | 19 |
| 31 Mar 19 | 7,659 | 785 | 1,958 | 9 |
| 31 Dec 18 | 7,511 | 683 | 1,839 | 0 |
| 30 Sep 18 | 7,395 | 373 | 1,779 | 28 |
| 30 Jun 18 | 7,280 | 64 | 1,719 | 56 |
| 31 Mar 18 | 7,053 | 73 | 1,697 | 28 |
| 31 Dec 17 | 6,827 | 82 | 1,675 | 0 |
| 30 Sep 17 | 6,640 | -34 | 1,688 | 3 |
| 30 Jun 17 | 6,454 | -150 | 1,702 | 5 |
| 31 Mar 17 | 6,266 | -211 | 1,687 | 3 |
| 31 Dec 16 | 6,078 | -272 | 1,672 | 0 |
| 30 Sep 16 | 6,083 | -216 | 1,671 | 5 |
| 30 Jun 16 | 6,076 | -159 | 1,667 | 9 |
| 31 Mar 16 | 6,195 | -32 | 1,663 | 5 |
| 31 Dec 15 | 6,446 | 92 | 1,695 | 0 |
| 30 Sep 15 | 6,597 | 148 | 1,684 | -12 |
| 30 Jun 15 | 6,711 | 201 | 1,665 | -23 |
| 31 Mar 15 | 6,565 | 373 | 1,621 | -12 |
| 31 Dec 14 | 6,422 | 545 | 1,577 | 0 |
| 30 Sep 14 | 6,179 | 552 | 1,505 | 4 |
| 30 Jun 14 | 6,101 | 574 | 1,473 | 8 |
| 31 Mar 14 | 6,112 | 306 | 1,452 | 4 |
| 31 Dec 13 | 5,972 | 38 | 1,396 | 0 |
Quality Earnings: 3933 has high quality earnings.
Growing Profit Margin: 3933's current net profit margins (20.8%) are higher than last year (17.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 3933's earnings have grown significantly by 33.8% per year over the past 5 years.
Accelerating Growth: 3933's earnings growth over the past year (30.1%) is below its 5-year average (33.8% per year).
Earnings vs Industry: 3933 earnings growth over the past year (30.1%) exceeded the Pharmaceuticals industry 9.4%.
Return on Equity
High ROE: 3933's Return on Equity (21.4%) is considered high.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 07:39 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
The United Laboratories International Holdings Limited is covered by 32 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ying Shao | BofA Global Research |
| Yue-Kwong Lui | CGS International |
| Bo Yu | China International Capital Corporation Limited |